Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (DE:XCY)
FRANKFURT:XCY
Holding DE:XCY?
Track your performance easily
XCY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.79 - €1.89
Previous Close€1.24
Volume0.00
Average Volume (3M)N/A
Market Cap
€883.22M
Enterprise Value€1.08B
Total Cash (Recent Filing)$95.88M
Total Debt (Recent Filing)$308.75M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Aug 01, 2024EPS Estimate
-€0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding696,991,677
10 Day Avg. Volume100
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)0.92
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.25
Enterprise Value/Gross Profit3.39
Enterprise Value/Ebitda-15.68
Forecast
1Y Price Target
€2.91Price Target Upside135.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Opko Health News
PremiumCompany Announcements
Opko Health Subsidiary Restructures with Strategic Sale and Debt Settlement
Bulls Say, Bears Say
Bulls Say
Capital FundingThe sale of laboratory testing businesses to Labcorp provides $237.5M in non-dilutive capital, which will fund the development of novel therapeutics for BioReference.
DivestmentOPKO's agreement to divest around $100 million in annual revenue to Labcorp is expected to streamline BioReference Health’s laboratory services, allowing the company to focus on high-growth and high-margin operations.
Market PositioningPositive pharmacokinetic data for OPKO Health's oral GLP-2 candidate may position the company favorably within the $2.2B short bowel syndrome market.
Bears Say
EarningsOPKO’s first quarter financial results fell short both in terms of top-line performance and EPS relative to analyst modeling as well as consensus.
Financial PerformanceConsolidated total revenues were $173.7M, representing a 27% YoY decline and missing analyst projection of $180.0M.
RevenueNGENLA revenue came in lighter than the company had been expecting.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
XCY FAQ
What was Opko Health Inc’s price range in the past 12 months?
Opko Health Inc lowest stock price was €0.79 and its highest was €1.89 in the past 12 months.
What is Opko Health Inc’s market cap?
Currently, no data Available
When is Opko Health Inc’s upcoming earnings report date?
Opko Health Inc’s upcoming earnings report date is Aug 01, 2024 which is 79 days ago.
How were Opko Health Inc’s earnings last quarter?
Opko Health Inc released its earnings results on May 07, 2024. The company reported -€0.11 earnings per share for the quarter, missing the consensus estimate of -€0.087 by -€0.023.
Is Opko Health Inc overvalued?
According to Wall Street analysts Opko Health Inc’s price is currently Undervalued.
Does Opko Health Inc pay dividends?
Opko Health Inc does not currently pay dividends.
What is Opko Health Inc’s EPS estimate?
Opko Health Inc’s EPS estimate is -€0.09.
How many shares outstanding does Opko Health Inc have?
Currently, no data Available
What happened to Opko Health Inc’s price movement after its last earnings report?
Opko Health Inc reported an EPS of -€0.11 in its last earnings report, missing expectations of -€0.087. Following the earnings report the stock price went down -14.871%.
Which hedge fund is a major shareholder of Opko Health Inc?
Among the largest hedge funds holding Opko Health Inc’s share is Gamco Investors, Inc. ET AL. It holds Opko Health Inc’s shares valued at 216K.
---
Opko Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€2.91 (135.32% Upside)
€2.91 (135.32% Upside)
Blogger Sentiment
Bullish
DE:XCY Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $335.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.81%
12-Months-Change
Fundamentals
Return on Equity
-18.00%
Trailing 12-Months
Asset Growth
-9.02%
Trailing 12-Months
Company Description
Opko Health Inc
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
---
XCY Earnings Call
Q1 2024
0:00 / 0:00
---
XCY Stock 12 Month Forecast
Average Price Target
€2.91
▲(135.32% Upside)
Technical Analysis
Opko Health
―
Bausch Health Companies
―
Teva Pharmaceutical
―
Perrigo Company
―
Xencor
―
Best Analysts Covering XCY
1 Year
1 Year Success Rate
14/35 ratings generated profit
1 Year Average Return
+9.60%
reiterated a buy rating 5 months ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +9.60% per trade.
---